Genentech strikes second Asia deal in a week, betting up to $1B in oncology ADC alliance with DualityBio

Summary

Genentech announced a strategic alliance with DualityBio worth up to $1B focused on developing antibody-drug conjugates (ADCs) for oncology to address cancer drug resistance. This marks Genentech's second Asia-focused deal within a week.